Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Sysmex Corporation

Sysmex Corporation develops and provides diagnostic instruments and reagents for clinical laboratories and hospitals, self-described as focusing on healthcare advancement.

Medical Equipment Manufacturing

Sysmex Europe

Sysmex Asia Pacific

Sysmex America, Inc.

Sysmex France

Sysmex Corporation | 32,729 followers on LinkedIn. Together for a better healthcare journey | Sysmex Corporation is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of &quot;Together for a better healthcare journey.&quot;

Change Management | Innovation | AI

Hiro Wada

Associate Director IT | Supply Chain Business Intelligence | Visionary | Business Intelligence (BI) and Global Supply Chain (SC) Leader | MBA Data…

Nadeem Khan

Channel Partner at Sysmex Corporation

Kaustubha Devi

Audiovisual Production Specialist

Aaron White

This week is World AMR Awareness Week. Antimicrobial Resistance ( #AMR ) is a global issue demanding immediate attention as antibiotics become less effective. We share stories highlighting the importance of diagnostics in AMR countermeasures. Read more on our Stories 👇 https://lnkd.in/eUckA4W8 #WAAW #Astrego #AMRfighter

Sysmex is pioneering gene panel testing for Inherited Retinal Dystrophy (IRD), one of the rare, intractable eye diseases. This innovative test, first clinically implemented in Japan in 2023, aims to improve the #QualityOfLife for patients and their families by identifying the causative genes responsible for IRD. Discover the journey and dedication of our team in implementing this new testing system. Watch the video and read more here 👇 https://lnkd.in/gzxGz9u5 #SysmexStories #GeneticTesting #RareDiseases

Sysmex has published the Sysmex Report 2024, an integrated report that concisely summarizes financial and non-financial information for stakeholders to understand Sysmex’s value creation in the medium to long term. A reporting tool to complement the Sysmex Report, the Sysmex Sustainability Data Book 2024 has also been published at the same time. The Sustainability Data Book describes a whole host of specific efforts to address priority issues (materiality) in sustainability. https://lnkd.in/dVNZgfMA

The Sysmex Group participates in the Pink Ribbon Campaign, a global awareness campaign for breast cancer. October is a special month for the Pink Ribbon Campaign, and Sysmex has been conducting various initiatives as part of its #PINKTOBER activities. https://lnkd.in/eyzYnCQR #BreastCancerAwareness #pinkribbon #SysmexGivesBack #SDGs #Sustainability

#UnderstandingSysmex 🌟 What's our Growth Potential? Sysmex aims to enhance the healthcare journey by creating further innovations in in vitro diagnostics, as well as providing unique value in the areas of personalized medicine and novel treatments. We are targeting net sales of ¥1 trillion or more by fiscal 2033. What are the three growth strategies to achieve this goal? Learn more here👇 https://lnkd.in/dvTPA4W4 #GrowthStrategy

With remarkable technological advancements, the era of #PersonalizedMedicine , which provides optimal medical care tailored to each individual, has arrived in the medical world. In just one minute, we will introduce what “Personalized Medicine” is and Sysmex‘s efforts to support its realization.🎥 For more information, click here👇 https://lnkd.in/d32bH8iw #UnderstandingSysmex

#UnderstandingSysmex 🌟 What does our long-term vision “Together for a better healthcare journey” mean? Sysmex is committed to fulfilling the universal desire of people to live long and healthy lives. What is the aspiration behind our long-term vision？🎥 For more information, click here👇 https://lnkd.in/dQSfaKRn #healthcarejourney

#UnderstandingSysmex 🌟 What we do? Since its foundation in 1968, Sysmex has focused on the field of in vitro diagnostics, supporting the health of people in over 190 countries and regions worldwide. We are proud to hold the No.1 global market share in three fields of in vitro diagnostics: hematology, hemostasis, and urinalysis. Please refer to this video for an introduction to our business.🎥

Sysmex is leveraging over 50 years of expertise in in vitro diagnostics. Together with a range of partners, we strive to develop new testing and diagnostic technologies that contribute to the early diagnosis and treatment of #dementia . In an interview, our Chief Technology Officer, Tomokazu Yoshida, talks about his determination and struggle to establish a new testing method in the field of dementia.🎥 Read more on our Stories👇 https://lnkd.in/g4wtqwF2 #KnowAlzheimers #WorldAlzheimersDay #WorldAlzMonth

This year's theme for #WorldAlzMonth is ‘Time to Act on Dementia, Time to Act on Alzheimers’. By 2050, the number of dementia patients worldwide is expected to reach 140 million, with many cases being #AlzheimersDisease . Learn about the importance of early detection and diagnosis of Alzheimer's disease and how Sysmex's blood testing is paving the way for more accessible diagnosis.🎥 https://lnkd.in/gJDmV8gT #TimeToActOnDementia #TimeToActOnAlzheimers #KnowAlzheimers #WorldAlzheimersDay

6869

JP:CO:SYSMEX

Sysmex Corporation

Last Close

3,072.00

21/11 06:45

Market Cap

1.60T

Beta: -

Volume Today

944K

Avg: -